pRBC
Showing 26 - 50 of 198
Beta-Thalassemia Trial in Worldwide (LentiGlobin BB305 Drug Product)
Active, not recruiting
- Beta-Thalassemia
- LentiGlobin BB305 Drug Product
-
Oakland, California
- +8 more
Feb 4, 2022
Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in
Recruiting
- Autoimmune Hemolytic Anemia
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Mar 9, 2022
Aortic Regurgitation Trial in Beijing (TaurusTrio™ Heart Valve System)
Recruiting
- Aortic Regurgitation
- TaurusTrio™ Heart Valve System
-
Beijing, China首都医科大学附属北京安贞医院
Oct 20, 2023
Cancer, Tumour, Surgery Trial in Canada, United States (Tranexamic acid (TXA), Normal saline)
Active, not recruiting
- Cancer
- +2 more
- Tranexamic acid (TXA)
- Normal saline
-
Rochester, Minnesota
- +10 more
Oct 25, 2022
MDS Trial in Tampa (Canakinumab Injection, Darbepoetin Alfa)
Recruiting
- Myelodysplastic Syndromes
- Canakinumab Injection
- Darbepoetin Alfa
-
Tampa, FloridaMoffitt Cancer Center
Nov 21, 2022
ß-thalassemia Trial in Shenzhen (ß-globin restored autologous hematopoietic stem cells)
Recruiting
- β-thalassemia
- β-globin restored autologous hematopoietic stem cells
-
Shenzhen, Guangdong, ChinaShenzhen Children's Hospital
Feb 24, 2023
Sickle Cell Disease Trial in Birmingham, Palo Alto, Saint Louis (GPH101 Drug Product)
Active, not recruiting
- Sickle Cell Disease
- GPH101 Drug Product
-
Birmingham, Alabama
- +2 more
Jan 5, 2023
Warm Autoimmune Hemolytic Anemia Trial in Riverside (ALXN1830, Placebo)
Withdrawn
- Warm Autoimmune Hemolytic Anemia
- ALXN1830
- Placebo
-
Riverside, CaliforniaClinical Study Site
Feb 2, 2022
Sickle Cell Disease Trial in United States (bb1111)
Recruiting
- Sickle Cell Disease
- bb1111
-
Birmingham, Alabama
- +8 more
Jul 15, 2022
Mild to Moderate Acute Respiratory Distress Syndrome Trial in France (PrismaLung+)
Recruiting
- Mild to Moderate Acute Respiratory Distress Syndrome
- PrismaLung+
-
Besançon, France
- +8 more
Dec 29, 2022
Paroxysmal Hemoglobinuria, Nocturnal Trial in Worldwide (Crovalimab, Placebo)
Active, not recruiting
- Paroxysmal Hemoglobinuria, Nocturnal
- Crovalimab
- Placebo
-
Paris, France
- +18 more
Dec 5, 2022
ß-thalassemia Trial (BD211)
Not yet recruiting
- β-thalassemia
- BD211
- (no location specified)
Mar 15, 2023
ß-thalassemia Trial in Shanghai (BD211)
Not yet recruiting
- β-thalassemia
- BD211
-
Shanghai, ChinaShanghai Ruijin Hospital
Mar 16, 2023
Evaluate the Impact of Eculizumab in Korean PNH Patients
Completed
- PNH
-
Seoul, Korea, Republic ofHandok
Apr 14, 2022
MDS, Del(5Q), Anemia Trial in Italy (Luspatercept Injection [Reblozyl])
Recruiting
- Myelodysplastic Syndromes
- +3 more
- Luspatercept Injection [Reblozyl]
-
Alessandria, Italy
- +22 more
Jun 20, 2023
Aortic Valve Replacement Trial in China (EDWARDS INSPIRIS RESILIA Aortic Valve)
Recruiting
- Aortic Valve Replacement
- EDWARDS INSPIRIS RESILIA Aortic Valve
-
Xiamen, Fujian, China
- +5 more
Oct 19, 2022
Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria Trial in Worldwide (Pegcetacoplan)
Recruiting
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Paroxysmal Hemoglobinuria
-
Atlanta, Georgia
- +9 more
Jul 18, 2022
MDS, Thrombocytopenia Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (Eltrombopag)
Completed
- Myelodysplastic Syndromes
- Thrombocytopenia
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Mar 8, 2022
Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD Trial run by the National Heart, Lung, and Blood
Not yet recruiting
- Immune Mediated Anemia
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
Fanconi Anemia Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (Eltrombopag)
Recruiting
- Fanconi Anemia
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 28, 2023
Carcinoma, Renal Cell Trial in Pittsburgh (Autologous alpha-DC1/TBVA vaccine, Cabozantinib)
Not yet recruiting
- Carcinoma, Renal Cell
- Autologous alpha-DC1/TBVA vaccine
- Cabozantinib
-
Pittsburgh, PennsylvaniaUPMC Department of Urology
Jan 5, 2023
Intraoperative Transfusion Practice in Children
Completed
- Transfusion
-
Frankfurt, NRW, GermanyDepartment of Anaesthesiology, Intensive Care Medicine and Pain
Aug 23, 2021
Burns Trial in Riyadh (Enoxaparin 40 mg q24 hours, Enoxaparin 30 mg q12 hours, Unfractionated heparin 5000 U q8 hours)
Completed
- Burns
- Enoxaparin 40 mg q24 hours
- +2 more
-
Riyadh, Saudi ArabiaKing Abdulaziz Medical City
Dec 17, 2022